Skip to main content

Table 3 Changes in body composition and bone mineral density between 3 and 24 months

From: Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months

    P value
  Treatment A (n= 14) Treatment B (n= 11) Time Treatment × Compliance × Time
Body mass index (kg/m2) 0.54 (-0.37 to 1.44) 0.89 (-0.13 to 1.91) 0.07 0.37
Fat mass (kg) 0.36 (-1.54 to 2.25) 3.77 (1.63 to 5.90) 0.028 0.040
Fat mass index (kg/m2) 0.05 (-0.62 to 0.72) 1.24 (0.48 to 2.00) 0.035 0.035
Fat (%) 0.15 (-2.03 to 1.73) 2.80 (0.67 to 4.91) 0.11 0.17
Trunk/peripheral fat ratio 0.15 (-0.05 to 0.36) 0.18 (-0.05 to 0.42) 0.18 0.82
Trunk fat (kg) -0.01 (-1.26 to 1.25) 1.11 (-1.95 to 4.17) 0.40 0.36
Lean body mass (kg) 1.12 (-0.06 to 2.30) 0.52 (-0.81 to 1.86) 0.007 0.79
Appendicular lean mass (kg) 0.08 (-0.65 to 0.80) 0.25 (-0.56 to 1.07) 0.26 0.83
Fat-free mass 1.23 (0.08 to 2.38) 0.57 (-0.73 to 1.87) 0.004 0.69
Fat-free mass index 0.29 (-0.15 to 0.72) 0.16 (-0.33 to 0.65) 0.011 0.63
L2 to L4     
   BMD (g/cm2) 0.02 (-0.01 to 0.05) 0.03(0.00 to 0.06) 0.15 0.56
   Z score 0.31 (0.06 to 0.57) 0.29 (0.00 to 0.58) 0.030 0.26
   T score 0.26 (-0.03 to 0.55) 0.26 (-0.03 to 0.55) 0.20 0.55
   BMD (g/cm2) 0.00 (-0.02 to 0.02) 0.01 (-0.03 to 0.01) 0.19 0.63
   Z score 0.12 (-0.06 to 0.30) 0.04 (-0.24 to 0.17) 0.24 0.63
   T score 0.01 (-0.14 to 0.17) 0.12 (-0.29 to 0.06) 0.20 0.32
  1. Changes in body composition and bone mineral density (BMD) between 3 and 24 months, using a mixed linear model. Data presented as mean (95% confidence interval). Treatment A, methotrexate + sulphasalazine + hydroxychloroquine; treatment B, methotrexate +infliximab. Changes between 3 and 12 months and patients not compliant to respective treatment are not presented. P values given for the interactions with the main factor Time and the interactions with factor Time. Bold values are statistically significant.